Alder Pharmaceuticals

Alder Pharmaceuticals:

The podium presentation of Alder Pharmaceuticals was full of great scientific data and information. Alder is focusing its

research goals on the development of antibodies to be used as a therapeutic method to combat inflammation caused by

cancer. In the past, they developed an outstanding method to manufacture high quality antibodies. This method has resulted

in therapeutic antibodies that are very efficient, which substantially lowers the price of treatment. The manufacturing

system, called Mab Xpress, has allowed the company to enter more efficiently into new markets. In fact, Alder is well-

funded: they just raised $38 million in April 2012. At this year's LSINW conference, Alder is presenting its newest

development: two antibodies, called ALD403 and ALD317, which are targeted to reduce migraine and dyslipidemia,

respectively. For migraines, they have been developing a therapeutic antibody whose target is CGRP (calcitonin gene

related peptide). The drug acts in the periphery of the nervous system. So far, the drug has passed Phase I of R&D. During

Phase I, Alder proved that the drug prevents the start of a migraine. The drug has 72% viability. This year, Alder is moving

this drug into Phase II. The study design is now completed.

Alder is still very proud of the outstanding success of their previous drug, Clazakizumab, which is very effective in treating

rheumatoid arthritis, with 43% patient remission.